Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of “Moderate Buy” by Brokerages

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been given an average rating of “Moderate Buy” by the eight analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.70.

VNDA has been the topic of several recent analyst reports. Wall Street Zen lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. B. Riley Financial restated a “buy” rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright lowered their target price on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, August 10th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Torren Management LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $25,000. Quantbot Technologies LP acquired a new position in Vanda Pharmaceuticals in the 2nd quarter worth about $29,000. Russell Investments Group Ltd. raised its position in Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares during the last quarter. Legal & General Group Plc bought a new position in Vanda Pharmaceuticals in the second quarter valued at about $34,000. Finally, Allworth Financial LP acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at about $43,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Stock Performance

VNDA opened at $5.57 on Thursday. The firm has a market cap of $336.76 million, a P/E ratio of -1.20 and a beta of 0.64. Vanda Pharmaceuticals has a 52-week low of $4.27 and a 52-week high of $9.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.60 and a current ratio of 1.61. The business’s fifty day moving average is $5.64 and its 200-day moving average is $6.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. The company had revenue of $50.53 million during the quarter, compared to analyst estimates of $61.92 million. Sell-side analysts expect that Vanda Pharmaceuticals will post -3 EPS for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.